Seminars in arthritis and rheumatism
-
Semin. Arthritis Rheum. · Aug 2010
ReviewIs remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis?
To contrast and compare the spectrum of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) with rheumatoid arthritis (RA) using an illustrative case. ⋯ Based on the clinical, laboratory, suspected infectious etiology, genetic differences, and types of associated malignancies, RS3PE appears to be a distinct entity rather than a subset of RA.
-
Semin. Arthritis Rheum. · Jun 2010
Randomized Controlled Trial Multicenter StudyLong-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.
-
Semin. Arthritis Rheum. · Jun 2010
ReviewSleep as a marker in the effective management of chronic osteoarthritis pain with opioid analgesics.
Sleep disturbances frequently accompany chronic pain from osteoarthritis (OA), and their effective management may reflect successful treatment of chronic pain. The objective of this article is to provide a rationale for using improvement in sleep as a marker for effective management of chronic OA pain with opioid analgesics. For this purpose, available evidence evaluating the relationship between successful management of chronic pain with opioids and improvements in sleep in patients with OA is reviewed. ⋯ Current evidence suggests that various long-acting opioid analgesics simultaneously achieve pain control and improve sleep. However, the complex interaction between reduced pain and improved sleep requires further study.
-
Semin. Arthritis Rheum. · Apr 2010
ReviewThe risk of infections with biologic therapies for rheumatoid arthritis.
To assess the risk of serious and nonserious bacterial and viral infections associated with the use of biologic therapy (abatacept, adalimumab, anakinra, etanercept, infliximab, and rituximab) in patients with rheumatoid arthritis (RA). ⋯ All marketed TNF inhibitors for compared to control RA appear to increase the risk of serious and nonserious infections compared with DMARDs. Although suggestive, data for abatacept and rituximab are less definitive and longer periods of patient exposure to these agents are needed before an assessment of their risks can be made.
-
Semin. Arthritis Rheum. · Feb 2010
Determinants of morbidity and mortality of systemic sclerosis in Canada.
To describe the morbidity and mortality in Canadian scleroderma (SSc) patients focusing on gender, SSc type, and organ-specific prognosis in a cohort of patients seen from 1994 to 2004 in a Southwestern Ontario SSc clinic. We also compared this cohort to data from the literature, which showed that mean survival in recent studies has risen to 72 months versus 48 months in earlier studies. ⋯ We conclude that cardiac involvement, dcSSc, and hypertension are associated with worse survival, and survival of patients with scleroderma is improving compared with older reports in the literature.